KR970703752A - 액체 제제 내의 약물 투여용 제형(Dosage form for Administering Drug in Liquid Formulation) - Google Patents

액체 제제 내의 약물 투여용 제형(Dosage form for Administering Drug in Liquid Formulation)

Info

Publication number
KR970703752A
KR970703752A KR1019960707046A KR19960707046A KR970703752A KR 970703752 A KR970703752 A KR 970703752A KR 1019960707046 A KR1019960707046 A KR 1019960707046A KR 19960707046 A KR19960707046 A KR 19960707046A KR 970703752 A KR970703752 A KR 970703752A
Authority
KR
South Korea
Prior art keywords
drug
group
formulation
glycols
wall
Prior art date
Application number
KR1019960707046A
Other languages
English (en)
Other versions
KR100360636B1 (ko
Inventor
스티븐 디. 라슨
죠지 브이. 귀타드
패드릭 에스. 엘. 웡
Original Assignee
스티븐 에프. 스톤
앨자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 에프. 스톤, 앨자 코포레이션 filed Critical 스티븐 에프. 스톤
Publication of KR970703752A publication Critical patent/KR970703752A/ko
Application granted granted Critical
Publication of KR100360636B1 publication Critical patent/KR100360636B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

비수성 담체 내의 약물(22)를 생물학적 사용 환경 내로 전달하기 위한 제형 (10)이 기재된다.

Description

액체 제제내의 약물 투여용 제형(Dosage form for Administering Drug in Liquid Formulation)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 제형이 (a)반투과성 중합체로 구성된 외벽, (b)단백질 중합체로 구성된 내벽; (c)외벽 및 내벽에 의해 형성된 내부 구획; (d)내부 구획 내의 압박 조성물; (e)제형의 내부와 외부를 연결하는 내벽 및 외벽 내의 배출구로 구성되며; 상기 제형이 (1)비(非)-펩티드 및 펩티드 약물로 구성된 군으로부터 선택된 약품 및 (2) 수소첨가된 글리세리드, 모노글리세리드,디글리세리드 및 트리글리세리드로 이루어진 군으로부터 선택된 물질,(3) 글리콜, 폴리알킬렌 글리콜 및 글리콜의 에스테르로 이루어진 군으로부터 선택된 물질, 및 (4) 수소 첨가된 오일을 포함하는, 약물을 위한 담체를 함유하는 내부 구획 내의 약물 조성물로 특징지워진, 사용 환경에 약물을 투여하기 위한 제형.
  2. 제1항에 있어서, 상기 약물이 모노펩티드, 디펩티드, 트리펩티드,폴리펩티드, 단백질, 효소, 핵단백질, 당단백질, 지단백질 및 면역 치료 펩티드로 이루어진 군으로부터 선택된 약물인, 사용 환경에 약물을 투여하기 위한 제형.
  3. 제1항에 있어서, 상기 약물이 시클로스포린인, 사용 환경에 약물을 투여하기 위한 제형.
  4. (a)비-펩티드 및 펩티드 약물로 구성된 군으로부터 선택된 약물; 수소 첨가된 오일; 및 글리콜, 폴리알킬렌 글리콜 및 글리콜의 에스테르로 이루어진 군으로부터 선택된 물질로 이루어진 약물 조성물; 및 (b)장시간 및 연장 시간 동안의 약물 방출 패턴의 제어된 전달로 특징지워진, 사용 환경에 약물을 투여하기 위한 체형.
  5. 제4항에 있어서, 상기 약물이 시클로스포린인, 사용 환경에 약물을 투여하기 위한 제형.
  6. (a)비(非)-펩티드 및 펩티드 약물로 구성된 군으로부터 선택된 약물; 수소 첨가된 오일; 수소첨가된 글리세리드, 모노글리세리드, 디글리세리드 및 트리글리세리드로 구성된 군으로부터 선택된 물질을 포함하는 약물 조성물;(b) 장시간 및 연장 시간 동안의 약물 방출 패턴의 제어된 방출로 특징지워진, 사용 환경에 약물을 투여하기 위한 체형.
  7. 제6항에 있어서, 상기 약물이 시클로스포린인, 사용 환경에 약물을 투여하기 위한 체형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960707046A 1994-06-13 1994-06-13 액체제제내의약물투여용제형 KR100360636B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/006723 WO1995034285A1 (en) 1994-06-13 1994-06-13 Dosage form for administering drug in liquid formulation

Publications (2)

Publication Number Publication Date
KR970703752A true KR970703752A (ko) 1997-08-09
KR100360636B1 KR100360636B1 (ko) 2002-12-18

Family

ID=22242671

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960707046A KR100360636B1 (ko) 1994-06-13 1994-06-13 액체제제내의약물투여용제형

Country Status (11)

Country Link
EP (1) EP0768867B1 (ko)
JP (1) JP3901727B2 (ko)
KR (1) KR100360636B1 (ko)
AT (1) ATE225647T1 (ko)
AU (1) AU682703B2 (ko)
CA (1) CA2185119C (ko)
DE (1) DE69431533T2 (ko)
DK (1) DK0768867T3 (ko)
ES (1) ES2183841T3 (ko)
PT (1) PT768867E (ko)
WO (1) WO1995034285A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
EP1023441A1 (en) 1997-10-16 2000-08-02 The Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
EP1112060B1 (en) * 1998-09-09 2005-12-07 ALZA Corporation Dosage form comprising liquid formulation
WO2000035419A2 (en) * 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AR041744A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
ES2909803T3 (es) 2018-03-05 2022-05-10 Amneal Complex Products Res Llc Composiciones farmacéuticas programables para la cronoliberación de fármacos
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
EP3934622A1 (en) 2019-03-05 2022-01-12 Amneal Complex Products Research LLC Delayed release methylphenidate compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug

Also Published As

Publication number Publication date
DE69431533T2 (de) 2003-10-02
PT768867E (pt) 2003-01-31
AU7108094A (en) 1996-01-05
JP3901727B2 (ja) 2007-04-04
AU682703B2 (en) 1997-10-16
DE69431533D1 (de) 2002-11-14
JPH10501261A (ja) 1998-02-03
EP0768867A1 (en) 1997-04-23
ATE225647T1 (de) 2002-10-15
CA2185119A1 (en) 1995-12-21
CA2185119C (en) 2005-07-26
EP0768867B1 (en) 2002-10-09
DK0768867T3 (da) 2002-10-28
KR100360636B1 (ko) 2002-12-18
ES2183841T3 (es) 2003-04-01
WO1995034285A1 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
KR970703752A (ko) 액체 제제 내의 약물 투여용 제형(Dosage form for Administering Drug in Liquid Formulation)
ES2196918T3 (es) Sistema de suministro osmotico dotado de piston con economia de espacio..
DK0464140T3 (da) Aktivt adhæsionspeptid
ID28275A (id) Penghantaran kolon dan enterik yang menggunakan kapsul-kapsul hpmc
NO995313D0 (no) Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
DE69615838T2 (de) Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
RU94028653A (ru) Фармацевтический препарат
BR9807555A (pt) Recipiente distribuidor de múltiplas câmaras
HUP9900346A3 (en) Endoparasiticidal pharmaceutical compositions containing avermectines and depsipeptides
AU5668100A (en) Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
AR005274A1 (es) Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante.
DE69520475T2 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
FR2719593B1 (fr) Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
SE9501631D0 (sv) Device for mixing a pharmaceutical composition with another agent
NL1000332C1 (nl) Graduele chemische modificatie van biologisch actieve peptiden en eiwitten.
ATE292173T1 (de) Lipidspaltender enzymkomplex
RU2003125460A (ru) Биологически активный комплекс, содержащий фосфолипиды, для терапевтического использования
DE69728769D1 (de) Polymerzusammensetzung zur oralen administration von peptiden und proteinen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071026

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee